MX358134B - Antagonistas del receptor st2l y metodos de uso. - Google Patents
Antagonistas del receptor st2l y metodos de uso.Info
- Publication number
- MX358134B MX358134B MX2014013200A MX2014013200A MX358134B MX 358134 B MX358134 B MX 358134B MX 2014013200 A MX2014013200 A MX 2014013200A MX 2014013200 A MX2014013200 A MX 2014013200A MX 358134 B MX358134 B MX 358134B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antagonists
- st2l
- st2l antagonists
- fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Catching Or Destruction (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261640407P | 2012-04-30 | 2012-04-30 | |
| US201261640238P | 2012-04-30 | 2012-04-30 | |
| US13/798,226 US9212227B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| US13/798,204 US9090694B2 (en) | 2012-04-30 | 2013-03-13 | ST2L antibody antagonists |
| PCT/US2013/038637 WO2013165894A2 (en) | 2012-04-30 | 2013-04-29 | St2l antagonists and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013200A MX2014013200A (es) | 2014-12-08 |
| MX358134B true MX358134B (es) | 2018-08-06 |
Family
ID=49477497
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013200A MX358134B (es) | 2012-04-30 | 2013-04-29 | Antagonistas del receptor st2l y metodos de uso. |
| MX2018009430A MX2018009430A (es) | 2012-04-30 | 2014-10-30 | Antagonistas del receptor st2l y metodos de uso. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009430A MX2018009430A (es) | 2012-04-30 | 2014-10-30 | Antagonistas del receptor st2l y metodos de uso. |
Country Status (37)
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2506871T1 (sl) * | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| US10053513B2 (en) | 2009-11-30 | 2018-08-21 | Janssen Biotech, Inc. | Antibody Fc mutants with ablated effector functions |
| US9090694B2 (en) * | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | Ų§ŁŲØŲ±ŁŲŖŁŁŲ§ŲŖ Ų§ŁŁ Ų±ŲŖŲØŲ·Ų© ŲØŁ ŁŁŲÆ Ų§ŁŁ Ų³ŲŖŲ¶Ų§ŲÆ st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | Ų§ŁŲ£Ų¬Ų³Ų§Ł Ų§ŁŁ Ų¶Ų§ŲÆŲ© ŁŁ Ų¶Ų§ŲÆ Ų§ŁŲŖŲ±ŁŁŁŁŁ-33 ŁŲ§Ų³ŲŖŲ¹Ł Ų§ŁŲ§ŲŖŁŲ§ |
| MX364591B (es) | 2013-03-15 | 2019-05-02 | Regeneron Pharma | Antagonistas de il-33 y usos de estos. |
| AU2015204674B2 (en) | 2014-01-10 | 2020-09-03 | Anaptysbio, Inc. | Antibodies directed against interleukin-33 (IL-33) |
| US10040859B2 (en) | 2014-04-21 | 2018-08-07 | The Children's Hospital Of Philadelphia | Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody |
| WO2015200073A1 (en) * | 2014-06-23 | 2015-12-30 | Bionomics, Inc. | Antibodies that bind lgr4 |
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | č±Ŗ夫čæĀ·ē½ę°ęéå ¬åø | Il-33ä»åƼåē¾ē ēę²»ēę¹ę³åčÆęę¹ę³ |
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CA2978449A1 (en) * | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| JP7114460B2 (ja) | 2015-06-26 | 2022-08-08 | ćµććć£ć»ćć¤ćŖććÆćććøć¼ | ć¢ććÆćć¼ćć«ęļ¼©ļ¼¬ļ¼ļ¼ļ¼²ļ¼”ļ½ļ¼°ęä½ |
| EA201891628A1 (ru) * | 2016-01-14 | 2018-12-28 | ŠŠ½Š°ŠæŃŠøŃŠ±Š°Š¹Š¾, ŠŠ½Šŗ. | ŠŠ½Š³ŠøŠ±ŠøŃŠ¾Š²Š°Š½ŠøŠµ Š°Š»Š»ŠµŃŠ³ŠøŃŠµŃŠŗŠ¾Š¹ ŃŠµŠ°ŠŗŃŠøŠø Ń ŠøŃŠæŠ¾Š»ŃŠ·Š¾Š²Š°Š½ŠøŠµŠ¼ ŠøŠ½Š³ŠøŠ±ŠøŃŠ¾ŃŠ° il-33 |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| EP3506920A4 (en) * | 2016-09-02 | 2020-05-27 | 180 Therapeutics LP | METHOD FOR TREATING SYSTEMIC FIBROTIC DISEASES WITH A BISPECIFIC IL-33 / TNF ANTIBODY |
| US20190225682A1 (en) * | 2016-09-02 | 2019-07-25 | 180 Therapeutics Lp | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
| JOP20190093A1 (ar) | 2016-10-28 | 2019-04-25 | Lilly Co Eli | Ų£Ų¬Ų³Ų§Ł Ł Ų¶Ų§ŲÆŲ© ŁŁ il-33 ŁŲ§Ų³ŲŖŲ®ŲÆŲ§Ł Ų§ŲŖŁŲ§ |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | ē¾ååēå é«č„å ¬åø | ę²»ēē¼ēēēēę¹ę³ |
| PE20191548A1 (es) | 2017-02-10 | 2019-10-24 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos |
| JP7205995B2 (ja) * | 2017-03-29 | 2023-01-17 | ćØćć»ćććć³ļ¼ć©ć»ćć·ć„ć»ć¢ćÆćć§ć³ć²ć¼ć«ć·ć£ćć | å ±åŗęæę§ļ½ļ½ļ½å容ä½ć«åƾććäŗéē¹ē°ę§ęåēµååå |
| AU2018252974B2 (en) | 2017-04-13 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| CN111527107B (zh) | 2017-12-21 | 2024-10-01 | č±Ŗ夫čæĀ·ē½ę°ęéå ¬åø | ē»åhla-a2/wt1ēęä½ |
| PE20211304A1 (es) | 2018-02-09 | 2021-07-20 | Genentech Inc | Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| CN113286814A (zh) * | 2018-10-31 | 2021-08-20 | å¾·éå°¼äŗå ¬åø | å¤ä»·č°čę§tē»čč°čå |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | ģ£¼ģķģ¬ ķ¬ė¦ģ¤ėÆøģ¤ | ģģ ģ±ģ“ ķ„ģė ķ c-Met ķģ²“ ėė ź·øģ ķģ ź²°ķ© ėØķø |
| CN110045131B (zh) * | 2019-06-14 | 2019-09-03 | čæåØ(äøęµ·)ēē©ē§ęęéå ¬åø | ēØäŗęµå®äŗŗil-33/st2éč·Æęå¶åēēē©å¦ę“»ę§ēę¹ę³ |
| CA3158366A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Anti il-33 therapeutic agent fpr treating renal disorders |
| JP2023500492A (ja) | 2019-11-04 | 2023-01-06 | ć”ćć¤ćć„ć¼ć³ć»ćŖćććć | ļ¼©ļ½ļ¼ļ¼ļ¼ć¢ć³ćæć“ćć¹ćć®ä½æēØę¹ę³ |
| US20230110203A1 (en) | 2020-03-13 | 2023-04-13 | Medimmune Limited | Therapeutic methods for the treatment of subjects with risk alelles in il33 |
| TW202144410A (zh) | 2020-03-13 | 2021-12-01 | ē¾åå»ŗåå¾·å å ¬åø | ęä»ē½ē“ ļ¼ļ¼ļ¼ęé«åå ¶ēØé |
| KR20220164555A (ko) | 2020-04-06 | 2022-12-13 | ė©ėė®Ø ė¦¬ėÆøķ°ė | Il-33 ģ¶ ź²°ķ© źøøķģ ė„¼ ģ¬ģ©ķ źøģ± ķøķ” ź³¤ė ģ¦ķźµ°ģ ģ¹ė£ |
| US20230272086A1 (en) | 2020-05-12 | 2023-08-31 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | St2 antigen binding protein |
| CN113501878B (zh) * | 2021-02-03 | 2022-12-02 | åäŗ¬ęŗä»ē¾åēē©ē§ęęéå ¬åø | éåƹäŗŗtslpēå¤ē§ęä½åå ¶ēØé |
| AR125753A1 (es) | 2021-05-04 | 2023-08-09 | Agenus Inc | Anticuerpos anti-tigit, anticuerpos anti-cd96 y mƩtodos de uso de estos |
| TW202322850A (zh) * | 2021-08-05 | 2023-06-16 | ē¾åē¾åē¦®ä¾å¤§č„å» | ęé«ęä½³å |
| EP4430072A1 (en) | 2021-11-10 | 2024-09-18 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| KR20240161653A (ko) * | 2022-02-24 | 2024-11-12 | ģė øė§ ė°ģ“ģ¤ģ¬ģ“ģøģ¤ ė¦¬ėÆøķ°ė | ģė¼ė„“ėƼģ ėķ ģ“ģ¤ ķ¹ģ“ģ ź²°ķ© ėØė°±ģ§ ė° ģ“ģ ģ©ė |
| CN115838425B (zh) * | 2022-08-31 | 2024-06-18 | é¦é½å»ē§å¤§å¦ | äøē§é¶åč”ē®”ē“§å¼ ē“ ii 1ååä½ē»čå¤ē¬¬äŗēÆēęä½åå ¶åŗēØ |
| AR130550A1 (es) | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | Anticuerpo anti-il-1r3 humanizado y mƩtodos de uso |
| CN119841936B (zh) * | 2024-12-30 | 2025-09-30 | äøå½åäøē§å¦é¢å °å·å ½å»ē ē©¶ę(äøå½åØē©å«ēäøęµč”ē å¦äøåæå °å·åäøåæ) | ęéę“²ēŖēē ęÆp72čē½äøåę§åå éęä½5d2åå ¶åŗēØ |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5869620A (en) | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikƶrpern |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikƶrpern auf phagenoberflƤchen ausgehend von antikƶrpersegmentbibliotheken |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| BR9606706A (pt) | 1995-10-16 | 1999-04-06 | Unilever Nv | AnĆ”logo de fragmento de anticorpo biespecĆfico ou bivalente uso processo para produzir o mesmo |
| AU4751697A (en) | 1996-10-10 | 1998-05-05 | Douglas Danner | Animal cell culture media comprising plant-derived nutrients |
| GB9727172D0 (en) | 1997-12-24 | 1998-02-25 | Univ Glasgow | Reagents specific for st2l and uses therefor |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des ƶffentlichen Rechts | Multivalente Antikƶrper-Konstrukte |
| GB9911569D0 (en) | 1999-05-18 | 1999-07-21 | Oxford Biomedica Ltd | Antibodies |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| AU2001218871A1 (en) | 2000-03-21 | 2001-10-03 | Takao Arai | Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | MolĆ©culas com semivida longa, composiƧƵes que as contĆŖm e suas utilizaƧƵes |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| US6649055B1 (en) | 2002-05-07 | 2003-11-18 | The United States Of America As Represented By The United States Department Of Energy | Pump station for radioactive waste water |
| US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
| AU2005209331A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| JP2008520204A (ja) | 2004-11-15 | 2008-06-19 | ć¤ć¼ć©ć¤ ćŖćŖć¼ ć¢ć³ć ć«ć³ććć¼ | éć¢ć·ć«åć°ć¬ćŖć³ęä½åć³ćć®ę²»ēćøć®ä½æēØ |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | äøå¤č£½č¬ę Ŗå¼ä¼ē¤¾ | ä¼åå¶å¾”ć«ććććŖććććč£½é ę¹ę³ |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| EP3018144A1 (en) | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| US20100260770A1 (en) | 2007-05-18 | 2010-10-14 | Medimmune, Llc | Il-33 in inflammatory disease |
| US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
| ES2564523T3 (es) | 2007-12-19 | 2016-03-23 | Janssen Biotech, Inc. | DiseƱo y generaciĆ³n de bibliotecas de presentaciĆ³n en fago por pIX de novo humanas mediante fusiĆ³n con pIX o pVII, vectores, anticuerpos y mĆ©todos |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | MĆ©todo de preparaĆ§Ć£o de molĆ©culas heterodimĆ©ricas de fc de anticorpos utilizando efeitos de induĆ§Ć£o eletrostĆ”tica |
| CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvieå ¬åø | åéåÆåē»ęåå ē«ēčē½åå ¶ēØé |
| JP2013516389A (ja) | 2009-01-06 | 2013-05-13 | ćć¤ć¢ććÆć¹ ć³ć¼ćć¬ć¼ć·ć§ć³ | ć«ćŖćÆć¬ć¤ć³é»å®³å¤ć«ććē²čēę²»ē |
| US8817596B2 (en) | 2009-01-09 | 2014-08-26 | Futurewei Technologies, Inc. | Protecting ingress and egress of a label switched path |
| US7879978B2 (en) * | 2009-03-31 | 2011-02-01 | Centocor Ortho Biotech, Inc. | Macaca fascicularis ST2L |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | ęčę¢ å¾·čÆåęéå ¬åø | å¶é å¼ęŗå¤čä½ååēę¹ę³ |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
| US20110206672A1 (en) | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
| SG184195A1 (en) | 2010-03-30 | 2012-11-29 | Janssen Biotech Inc | Humanized il-25 antibodies |
| EP3434694B1 (en) | 2010-04-09 | 2020-12-30 | Critical Care Diagnostics, Inc. | Soluble human st-2 antibodies and assays |
| CN110066339A (zh) | 2010-04-20 | 2019-07-30 | ę ¹é©¬åøč”ä»½å ¬åø | å«å¼äŗčä½ęä½fcēčē½åå ¶å¶å¤ę¹ę³ |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
| EP2621950A4 (en) | 2010-09-27 | 2015-09-02 | Janssen Biotech Inc | ANTIBODIES FOR BINDING HUMAN COLLAGEN II |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | ŠŠ°Š¹Š¼Š²Š¾ŃŠŗŃ ŠŠ½Šŗ. | ŠŠŠŠŠŠ Š£Š”Š¢ŠŠŠ§ŠŠŠŠŠ ŠŠŠ¢ŠŠ ŠŠŠŠŠŠ ŠŠŠŠ ŠŠŠ¢ŠŠ¢ŠŠŠ Š” ŠŠ£Š¢ŠŠ¦ŠŠÆŠŠ Š Fc ŠŠŠŠŠŠ |
| BR112013021473A2 (pt) | 2011-02-23 | 2020-08-04 | F. Hoffmann-La Roche Ag | anticorpos contra il33r humano e seus usos |
| US9090694B2 (en) * | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
| JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | Ų§ŁŲØŲ±ŁŲŖŁŁŲ§ŲŖ Ų§ŁŁ Ų±ŲŖŲØŲ·Ų© ŲØŁ ŁŁŲÆ Ų§ŁŁ Ų³ŲŖŲ¶Ų§ŲÆ st2 |
-
2013
- 2013-03-13 US US13/798,204 patent/US9090694B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/798,226 patent/US9212227B2/en not_active Expired - Fee Related
- 2013-04-29 EA EA201491996A patent/EA031047B1/ru not_active IP Right Cessation
- 2013-04-29 SI SI201331591T patent/SI2844292T1/sl unknown
- 2013-04-29 NZ NZ729913A patent/NZ729913A/en not_active IP Right Cessation
- 2013-04-29 CN CN201710188519.0A patent/CN107098973A/zh active Pending
- 2013-04-29 HU HUE13785158A patent/HUE045864T2/hu unknown
- 2013-04-29 AU AU2013256645A patent/AU2013256645B2/en not_active Ceased
- 2013-04-29 HR HRP20191884TT patent/HRP20191884T1/hr unknown
- 2013-04-29 SM SM20190639T patent/SMT201900639T1/it unknown
- 2013-04-29 NZ NZ702136A patent/NZ702136A/en not_active IP Right Cessation
- 2013-04-29 CN CN201380035058.3A patent/CN104411333B/zh not_active Expired - Fee Related
- 2013-04-29 BR BR112014027165A patent/BR112014027165A2/pt active Search and Examination
- 2013-04-29 KR KR1020207009560A patent/KR102147140B1/ko not_active Expired - Fee Related
- 2013-04-29 EA EA201891264A patent/EA201891264A3/ru unknown
- 2013-04-29 CA CA2871948A patent/CA2871948C/en not_active Expired - Fee Related
- 2013-04-29 DK DK13785158.0T patent/DK2844292T3/da active
- 2013-04-29 EP EP19192657.5A patent/EP3597219A1/en not_active Withdrawn
- 2013-04-29 ES ES13785158T patent/ES2755094T3/es active Active
- 2013-04-29 MY MYPI2014703188A patent/MY166062A/en unknown
- 2013-04-29 PT PT137851580T patent/PT2844292T/pt unknown
- 2013-04-29 EP EP13785158.0A patent/EP2844292B1/en active Active
- 2013-04-29 RS RS20191400A patent/RS59511B1/sr unknown
- 2013-04-29 WO PCT/US2013/038637 patent/WO2013165894A2/en not_active Ceased
- 2013-04-29 PE PE2014001920A patent/PE20150641A1/es active IP Right Grant
- 2013-04-29 NZ NZ74022113A patent/NZ740221A/en not_active IP Right Cessation
- 2013-04-29 UA UAA201412805A patent/UA118336C2/uk unknown
- 2013-04-29 MX MX2014013200A patent/MX358134B/es active IP Right Grant
- 2013-04-29 SG SG10201608525SA patent/SG10201608525SA/en unknown
- 2013-04-29 PL PL13785158T patent/PL2844292T3/pl unknown
- 2013-04-29 SG SG11201407028WA patent/SG11201407028WA/en unknown
- 2013-04-29 LT LT13785158T patent/LT2844292T/lt unknown
- 2013-04-29 JP JP2015510362A patent/JP6283354B2/ja not_active Expired - Fee Related
- 2013-04-29 KR KR1020147033310A patent/KR20150008152A/ko not_active Withdrawn
- 2013-04-30 UY UY0001034774A patent/UY34774A/es unknown
- 2013-04-30 AR ARP130101485A patent/AR090909A1/es not_active Application Discontinuation
- 2013-04-30 TW TW102115440A patent/TWI589588B/zh not_active IP Right Cessation
- 2013-04-30 TW TW106115697A patent/TWI687440B/zh not_active IP Right Cessation
- 2013-04-30 TW TW108132205A patent/TWI700299B/zh not_active IP Right Cessation
-
2014
- 2014-10-23 CR CR20140488A patent/CR20140488A/es unknown
- 2014-10-29 NI NI201400125A patent/NI201400125A/es unknown
- 2014-10-30 CO CO14240957A patent/CO7240389A2/es unknown
- 2014-10-30 EC ECIEPI201425178A patent/ECSP14025178A/es unknown
- 2014-10-30 MX MX2018009430A patent/MX2018009430A/es unknown
- 2014-10-30 IL IL235401A patent/IL235401B/en active IP Right Grant
- 2014-10-30 PH PH12014502435A patent/PH12014502435A1/en unknown
- 2014-10-30 CL CL2014002955A patent/CL2014002955A1/es unknown
-
2015
- 2015-11-12 US US14/939,624 patent/US9951137B2/en not_active Expired - Fee Related
-
2017
- 2017-04-20 AU AU2017202610A patent/AU2017202610B9/en not_active Ceased
- 2017-09-18 IL IL254569A patent/IL254569B/en active IP Right Grant
- 2017-11-06 JP JP2017213749A patent/JP6622274B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-15 US US15/922,136 patent/US10450377B2/en not_active Expired - Fee Related
- 2018-08-29 PH PH12018501839A patent/PH12018501839A1/en unknown
-
2019
- 2019-05-24 JP JP2019097226A patent/JP2019162136A/ja not_active Withdrawn
- 2019-11-20 CY CY20191101218T patent/CY1122308T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501839A1 (en) | St2l antagonists and methods of use | |
| GB2527254B (en) | Benzylisoquinoline alkaloids (BIA) Producing microbes, and methods of making and using the same | |
| MY198562A (en) | Antibodies specifically binding pd-1 and their uses | |
| MX349630B (es) | Alfa-amilasas. | |
| PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
| MX2019008212A (es) | Estructuras fibrosas que comprenden particulas y metodos para fabricarlas. | |
| PH12015501627A1 (en) | Kv1.3 antagonists and methods of use | |
| PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
| PH12016500598A1 (en) | Protoxin-ii variants and methods of use | |
| MX2017011223A (es) | Variantes de protoxina ii y metodos de uso. | |
| IN2014DN09798A (enExample) | ||
| MX2017012654A (es) | Variantes de protoxina-ii y metodos de uso. | |
| PH12016500826B1 (en) | Anti-ccl17 antibodies | |
| MX2015009161A (es) | Polioles, su preparaciĆ³n y su uso. | |
| MY184721A (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis | |
| UA80618U (en) | Use of n-steroylethanolamine as radiomodifier | |
| IN2013CH00453A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |